Investor Communication

In 1992, CMS was established in Shenzhen.

On 28 September 2010, CMS was listed on the Main Board of the Stock Exchange of Hong Kong Ltd. (stock code: 867); On 15 July 2025, CMS was secondary listed on the Main Board of the Singapore Exchange Securities Trading Ltd. (stock code: 8A8).

CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicating to providing competitive products and services to fulfill the unmet clinical needs.

CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the Cardiovascular-Kidney-Metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.

As of 31 December 2025, CMS has 6,415 employees, including about 5,000 professional academic promotional staff.

31 December each year.

Annual results announcement will be published no later than three months after the end of related financial year; interim results announcement will be published no later than two months after the end of first half of the financial year.

Deloitte Touche Tohmatsu is the auditor of CMS.

The electronic financial reports and announcements can be viewed and downloaded from the official website of SEHK (www.hkex.com.hk) or “Investor Relations” column of CMS’s official website.